Carcinoid syndrome classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 3: Line 3:
{{CMG}}{{AE}}{{Anum}}{{PSD}}
{{CMG}}{{AE}}{{Anum}}{{PSD}}
==Overview==
==Overview==
[[Gastroenteropancreatic]] [[neuroendocrine tumors]] are classified based upon their origin from the [[embryonic]] divisions of the [[alimentary tract]] into [[foregut]] [[Bronchial|(bronchial]], [[stomach]]), [[midgut]] ([[small intestine]], [[appendix]], [[cecum]]) and [[hindgut]] ([[Colon|distal colon]], [[rectum]], [[genitourinary]]) [[Tumour|tumours.]]
[[Gastroenteropancreatic]] [[neuroendocrine tumors]] are classified based on their origin from the [[embryonic]] divisions of the [[alimentary tract]] into [[foregut]] [[Bronchial|(bronchial]], [[stomach]]), [[midgut]] ([[small intestine]], [[appendix]], [[cecum]]) and [[hindgut]] ([[Colon|distal colon]], [[rectum]], [[genitourinary]]) [[Tumour|tumours.]]


==Classification==
==Classification==
*Gastroentero-pancreatic [[Neuroendocrine tumor|neuroendocrine tumors]] are classified based upon their origin from the [[embryonic]] divisions of the [[alimentary tract]]:
*Gastroentero-pancreatic [[Neuroendocrine tumor|neuroendocrine tumors]] are classified based on their origin from the [[embryonic]] divisions of the [[alimentary tract]]:
#[[Foregut]] [[Bronchial|(bronchial]], [[stomach]])
#[[Foregut]] [[Bronchial|(bronchial]], [[stomach]])
#[[Midgut]] ([[small intestine]], [[appendix]], [[cecum]])
#[[Midgut]] ([[small intestine]], [[appendix]], [[cecum]])
#[[Hindgut]] ([[Colon|distal colon]], [[rectum]], [[genitourinary]])
#[[Hindgut]] ([[Colon|distal colon]], [[rectum]], [[genitourinary]])
*[[GET|Gasroenteropancreatic]]- [[neuroendocrine tumor]] produce a number of [[secretory]] products, resulting in a wide range of clinica[[Symptoms|l symptoms.]]<ref name="pmid29260133">{{cite journal |vauthors=Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H |title=Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases |journal=Turk J Surg |volume=33 |issue=4 |pages=279–283 |date=2017 |pmid=29260133 |doi=10.5152/UCD.2017.3685 |url=}}</ref> <ref name="pmid26911175">{{cite journal |vauthors=Davies L, Weickert MO |title=Gastroenteropancreatic neuroendocrine tumours: an overview |journal=Br J Nurs |volume=25 |issue=4 |pages=S12–5 |date=2016 |pmid=26911175 |doi=10.12968/bjon.2016.25.4.S12 |url=}}</ref><ref name="pmid21311954">{{cite journal |vauthors=Oberg K, Castellano D |title=Current knowledge on diagnosis and staging of neuroendocrine tumors |journal=Cancer Metastasis Rev. |volume=30 Suppl 1 |issue= |pages=3–7 |date=March 2011 |pmid=21311954 |doi=10.1007/s10555-011-9292-1 |url=}}</ref>
*[[GET|Gasroenteropancreatic]]- [[neuroendocrine tumor]] produce a number of [[secretory]] products, resulting in a wide range of clinica[[Symptoms|l symptoms.]]<ref name="pmid29260133">{{cite journal |vauthors=Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H |title=Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases |journal=Turk J Surg |volume=33 |issue=4 |pages=279–283 |date=2017 |pmid=29260133 |doi=10.5152/UCD.2017.3685 |url=}}</ref> <ref name="pmid26911175">{{cite journal |vauthors=Davies L, Weickert MO |title=Gastroenteropancreatic neuroendocrine tumours: an overview |journal=Br J Nurs |volume=25 |issue=4 |pages=S12–5 |date=2016 |pmid=26911175 |doi=10.12968/bjon.2016.25.4.S12 |url=}}</ref><ref name="pmid21311954">{{cite journal |vauthors=Oberg K, Castellano D |title=Current knowledge on diagnosis and staging of neuroendocrine tumors |journal=Cancer Metastasis Rev. |volume=30 Suppl 1 |issue= |pages=3–7 |date=March 2011 |pmid=21311954 |doi=10.1007/s10555-011-9292-1 |url=}}</ref>
*[[Midgut]] [[gastrointestinal]] tract [[neuroendocrine tumor]] produce [[serotonin]] and other [[vasoactive]] [[substances]] that give rise to the typical [[Carcinoid Syndrome|carcinoid syndrome.]]
*[[Midgut]] [[gastrointestinal]] tract [[neuroendocrine tumor|neuroendocrine tumors]] produce [[serotonin]] and other [[vasoactive]] [[substances]] that causes the manifestations of typical [[Carcinoid Syndrome|carcinoid syndrome.]]
*[[Lung]] [[neuroendocrine tumors]] produce lesser quantities of [[serotonin]].
*[[Lung]] [[neuroendocrine tumors]] produce less quantities of [[serotonin]].
*[[Carcinoid Syndrome|Carcinoid syndrome]] is caused less commonly by [[lung]] [[neuroendocrine tumor]]  and most often with [[tumors]] of large [[size]] (>5 cm).
*[[Carcinoid Syndrome|Carcinoid syndrome]] is caused less commonly by [[lung]] [[neuroendocrine tumor]]  and most often by [[tumors]] of large [[size]] (>5 cm).





Revision as of 20:57, 30 April 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Anum Gull M.B.B.S.[2]Parminder Dhingra, M.D. [3]

Overview

Gastroenteropancreatic neuroendocrine tumors are classified based on their origin from the embryonic divisions of the alimentary tract into foregut (bronchial, stomach), midgut (small intestine, appendix, cecum) and hindgut (distal colon, rectum, genitourinary) tumours.

Classification

  1. Foregut (bronchial, stomach)
  2. Midgut (small intestine, appendix, cecum)
  3. Hindgut (distal colon, rectum, genitourinary)


Carcinoid syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Carcinoid Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carcinoid syndrome classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Carcinoid syndrome classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carcinoid syndrome classification

CDC on Carcinoid syndrome classification

Carcinoid syndrome classification in the news

Blogs on Carcinoid syndrome classification

Directions to Hospitals Treating Carcinoid syndrome

Risk calculators and risk factors for Carcinoid syndrome classification

Gastroenteropancreatic neuroendocrine tumors
Foregut Midgut Hindgut
Location
Hormones produced Variable
Possibility of carcinoid syndrome Rare, and atypical when it happens Classic Rare

References

  1. Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H (2017). "Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases". Turk J Surg. 33 (4): 279–283. doi:10.5152/UCD.2017.3685. PMID 29260133.
  2. Davies L, Weickert MO (2016). "Gastroenteropancreatic neuroendocrine tumours: an overview". Br J Nurs. 25 (4): S12–5. doi:10.12968/bjon.2016.25.4.S12. PMID 26911175.
  3. Oberg K, Castellano D (March 2011). "Current knowledge on diagnosis and staging of neuroendocrine tumors". Cancer Metastasis Rev. 30 Suppl 1: 3–7. doi:10.1007/s10555-011-9292-1. PMID 21311954.

Template:WH Template:WS